Bluejay Diagnostics (BJDX) Change in Account Payables (2020 - 2026)
Bluejay Diagnostics (BJDX) reported Change in Account Payables of $6033.0 for Q1 2026, down 98.39% on a YoY basis from $374402.0 in Q1 2025, and down 88.64% sequentially from $53093.0 in Q4 2025.
Bluejay Diagnostics (BJDX) Change in Account Payables (2020 - 2026) Analysis & Trends
Bluejay Diagnostics (BJDX) has 7 years of Change in Account Payables data on file, last reported at $6033.0 in Q1 2026.
- For the quarter ending Q1 2026, Change in Account Payables fell 98.39% year-over-year to $6033.0; the trailing twelve-month figure through Mar 2026 stood at -$299236.0 (down 220.81% YoY), and the FY2025 full-year result was $69133.0, up 119.96% from the prior year.
- Change in Account Payables retreated to $6033.0 in Q1 2026, from $53093.0 in the prior quarter.
- In the past five years, Change in Account Payables ranged from a high of $448199.0 in Q3 2023 to a low of -$520728.0 in Q2 2022.
- A 5-year average of -$31809.1 and a median of -$54392.0 in 2023 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 630.41% in 2022, while the deepest fall reached 789.36% in 2022.
- Tracing BJDX's Change in Account Payables over 5 years: stood at $97670.0 in 2022, then tumbled by 360.44% to -$254369.0 in 2023, then soared by 32.57% to -$171528.0 in 2024, then jumped by 130.95% to $53093.0 in 2025, then tumbled by 88.64% to $6033.0 in 2026.
- Business Quant data shows BJDX's Change in Account Payables at $6033.0 in Q1 2026, $53093.0 in Q4 2025, and $52345.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | - |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | -198.00 Mn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | - |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | - |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | - |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | - |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 221.00 Mn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Bluejay Diagnostics | 2,754.24 | 2,754.24 | - | 6,033.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,033.00 |
| Mar 31, 2026 | 6,033.00 |
| Dec 31, 2025 | 53,093.00 |
| Dec 31, 2025 | 53,093.00 |
| Sep 30, 2025 | 52,345.00 |
| Sep 30, 2025 | 52,345.00 |
| Jun 30, 2025 | -410,707.00 |
| Jun 30, 2025 | -410,707.00 |
| Mar 31, 2025 | 374,402.00 |
| Mar 31, 2025 | 374,402.00 |
| Dec 31, 2024 | -171,528.00 |
| Dec 31, 2024 | -171,528.00 |
| Sep 30, 2024 | -173,406.00 |
| Sep 30, 2024 | -173,406.00 |
| Jun 30, 2024 | 218,231.00 |
| Jun 30, 2024 | 218,231.00 |
| Mar 31, 2024 | -219,649.00 |
| Mar 31, 2024 | -219,649.00 |
| Dec 31, 2023 | -254,369.00 |
| Dec 31, 2023 | -254,369.00 |